Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species

Journal of Clinical Microbiology

Volumn 39, Issue 11, 2001, Pages 3952-3954

  Pfaller, M A ^a   Messer, S A ^a   Mills, K ^a   Bolmstrom A ^a   Jones, R N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; POSACONAZOLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CULTURE MEDIUM; DILUTION; ETEST METHOD; HUMAN; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STANDARD;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; HUMANS; MICROBIAL SENSITIVITY TESTS; TRIAZOLES;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; ISSATCHENKIA ORIENTALIS; PICHIA GUILLIERMONDII;

EID: 0034765581     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.39.11.3952-3954.2001     Document Type: Article

References (19)

1. In vitro activities of the new antifungal triazole SCH56592 against common and emerging yeast pathogens
2. Quality control limits for broth microdilution susceptibility tests of 10 antifungal agents
3. In vitro and in vivo activities of SCH56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida
4. Evaluation of the Etest system versus a microtitre broth method for antifungal susceptibility testing of yeasts against fluconazole and itraconazole
5. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
6. Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI1640 medium with 2% glucose
7. Antifungal agents and susceptibility tests
8. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryplococcus neoformans, and other pathogenic yeasts
9. Antibacterial susceptibility tests: Dilution and disk diffusion methods
10. Activity of a new triazole, SCH56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae
11. In vitro susceptibilities of Candida blood-stream isolates to the new triazole antifungal agents BMS-207147, SCH56592, and voriconazole
12. Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media
13. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B
14. Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media
15. In vitro susceptibility testing of filamentous fungi: Comparison of Etest and reference microdilution methods for determining itraconazole MICs
16. Comparison of Etest and broth microdilution methods for antifungal drug susceptibility testing of molds
17. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: Enhanced ability to detect amphotericin B-resistant Candida isolates
18. Candida, Crypotococcus, and other yeasts of medical importance